Welcome back to the PharmTech Weekly Roundup! I’m Susan Haigney, lead editor of PharmTech. There were some strategic investments made by industry this week, and FDA called out misleading claims about ...
FDA granted full approval to teclistamab plus daratumumab/hyaluronidase for RRMM after ≥1 prior line, marking first bispecific T-cell engager conversion from ...
Norgine invests £23 million in Wales site to modernize production and boost resilience for UK and European medicine supply chains.
FDA enforcement accelerated, with recent warning-letter volume exceeding the prior decade’s total, signaling a sustained departure from historical, reactive promotional oversight. “Sameness” ...
AI accelerates biopharma from discovery to production, cutting cycle times by up to 40%.
AI accelerates biopharma from discovery to production, cutting cycle times by up to 40%.
AI accelerates biopharma from discovery to production, cutting cycle times by up to 40%.
Proteomics-informed, genome-edited CHO design increased productivity up to three-fold and titers two-fold, strengthening CLD for novel biologics and biosimilars. Extended culture robustness was ...
The FDA's new era of proactive enforcement uses warnings to stop misleading GLP-1 ads and ensure a fair balance of drug risks and benefits.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results